2015
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.
Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. The Journal Of Clinical Psychiatry 2015, 76: 1075-84. PMID: 26214725, PMCID: PMC4560666, DOI: 10.4088/jcp.14m09123.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialObsessive-compulsive disorderSmall open-label trialsTreatment-refractory obsessive-compulsive disorderGlutamate modulator riluzoleSignificant residual symptomsOpen-label trialSubset of patientsDSM-IV obsessive-compulsive disorderBest available treatmentsPlacebo leadRiluzole groupRefractory symptomsPartial responseSignificant morbidityResidual symptomsModerate nauseaAvailable treatmentsStandard interventionGlutamate homeostasisRiluzoleSide effectsSRI treatmentPatientsSecondary analysis
2009
Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder
Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder. Journal Of Affective Disorders 2009, 121: 175-179. PMID: 19577308, PMCID: PMC3974618, DOI: 10.1016/j.jad.2009.06.010.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSRI responseSymptom dimensionsOpen-label continuation phaseClinical Global Improvement ScaleGlobal Improvement ScaleCentral serotonin systemInitial positive responseYale-Brown ObsessiveContinuation phaseMinor symptomsOrdinal logistic regressionClinical trialsSerotonin systemTreatment responseSame patientImprovement ScaleSRI treatmentPatientsSignificant associationLogistic regressionCompulsive ScaleOCD patientsOCD subjectsSymptoms